Elsevier

The Lancet

Volume 357, Issue 9256, 24 February 2001, Pages 608-609
The Lancet

Research Letters
Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease

https://doi.org/10.1016/S0140-6736(00)04063-0Get rights and content

Summary

Polymorphisms in the promoter region of the apolipoprotein E gene (APOE) affect the amount of amyloid peptide (Aβ) in the brains of patients with Alzheimer's disease. We measured Aβ load immunohistochemically in regions 8 and 9 of Brodman's area in 74 people with Alzheimer's disease. The amount of Aβ deposition was independent of APOE genotype in our cohort. These findings in patients with confirmed Alzheimer's disease are consistent with the hypothesis that variation in APOE expression directly affects Alzheimer's disease pathology.

References (5)

There are more references available in the full text version of this article.

Cited by (39)

  • Apolipoprotein E DNA methylation and posttraumatic stress disorder are associated with plasma ApoE level: A preliminary study

    2019, Behavioural Brain Research
    Citation Excerpt :

    The APOE-ε4 allele has been associated with the development of late-onset Alzheimer's disease (AD) [3]. However, amyloid beta (Aβ) peptide accumulation in the brains of AD patients has been shown to be independent of APOE genotype [4]. Additionally, the APOE-ε4 allele has been associated with poor outcome following stroke or brain injury [5], perhaps through an increased affinity for Aβ protein aggregation [6], or a decreased efficacy in promoting neuronal growth and branching [7].

  • Genetics of Alzheimer's disease: New evidences for an old hypothesis?

    2011, Current Opinion in Genetics and Development
    Citation Excerpt :

    In brain tissue from AD patients, the quantity of APOE mRNA is inversely correlated with the quantity of amyloid deposits [33]. Moreover, polymorphisms within the APOE promoter, associated with decreases in the in vitro and in vivo expression of this gene [33–35], are also associated with (i) an increase in the quantity of amyloid deposits [33,36] and (ii) a greater risk of developing AD [37]. If we then consider genes characterized by GWAS, CLU is one the most abundantly expressed apolipoproteins in the central nervous system [38,39].

  • Chapter 4 Alzheimer's Disease in Adults with Down Syndrome

    2008, International Review of Research in Mental Retardation
    Citation Excerpt :

    The Apolipoprotein E (APOE) gene, located on chromosome 19, is the most important genetic risk factor found thus far for late onset Alzheimer's disease in the typically developing population (Corder et al., 1993; Saunders et al., 1993). The APOE gene, which occurs predominately in three variants or alleles (i.e., ε2, ε3, or ε4), is involved in cholesterol transport and lipid metabolism in plasma (Dupuy et al., 2001) as well as accumulation of β‐amyloid protein in the brains of typically developing elderly people, both with and without Alzheimer's disease (Lambert et al., 2001; Polvikowski et al., 1995]. In numerous studies, participants with Alzheimer's disease have been found to have higher frequencies of the APOE ε4 allele compared with those with other APOE genotypes, and those with the ε4 allele have an earlier age of onset of Alzheimer's disease (Corder et al., 1993; de‐Andrade, Larrandaburu, Callegari‐Jacques, Gastaldo, & Hutz, 2000; Isbir et al., 2001; Mayeux et al., 1993).

View all citing articles on Scopus
View full text